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Editorial

Initial Invasive or Conservative Strategy for Stable
Coronary Disease: The ISCHEMIA Trial and Its
Clinical Implications
WHETHER OR NOT one should take an initial invasive or
conservative approach in the management of stable coronary
artery disease, lately named as chronic coronary syndrome
(CCS), has long been the subject of much debate.
The results of the recently published and highly anticipated
International Study of Comparative Health Effectiveness with
Medical and Invasive Approaches (ISCHEMIA) trial1 have
added fuel to this debate and have challenged the value of an
initial invasive strategy in patients with stable coronary artery
disease (CAD). The results of this trial have the potential to be
far-reaching and likely will influence future clinical practice
guidelines. Current recommendations from the European Society of Cardiology for the management of CCS reenforce the
importance of optimal medical therapy (OMT) in the management of stable CAD, primarily for symptom reduction and
slowing the disease process, while recommending myocardial
revascularization in specific CCS.2
The evolution of management strategies for patients with
stable CAD has called into question the long-term benefits of
an initial invasive strategy versus OMT on clinical outcomes.
Before the ischemia trial, arguably the most robust data
addressing this question came from the COURAGE and the
BARI 2D studies, and both of these trials failed to show significant differences in death and major adverse cardiovascular
events between the groups managed with an initial invasive
approach versus OMT.3,4 It should be noted, however, that
both of these trials have received criticism over perceived
selection bias and the lack of clarity in myocardial ischemia
thresholds for inclusion of patients in these trials.
The ISCHEMIA trial set out to address this with the intention of determining the effect of an invasive strategy (angiography and revascularization where feasible) in addition to
OMT in patients with stable CAD in patients with moderateto-severe ischemia. To date, this is the largest trial that has
been conducted to address this issue. Eligible patients were
randomized in a 1:1 fashion to either the initial invasive strategy in conjunction with OMT versus an initial conservative
group. This study ultimately randomized 5,179 patients. The
https://doi.org/10.1053/j.jvca.2021.05.055
1053-0770/Ó 2021 Elsevier Inc. All rights reserved.

primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key
secondary outcome was death from cardiovascular causes or
myocardial infarction.1
Patients included in this trial had to have at least moderate
ischemia on a qualifying stress test. Originally, this was moderate ischemia demonstrated on a stress echocardiogram, a
nuclear perfusion with single-photon emission computed
tomography or positron emission tomography, or cardiac magnetic resonance imaging; however, an amendment to the protocol was made in 2014 to include exercise stress testing without
imaging to improve recruitment. Most patients in this trial
(73%) underwent computed tomography coronary angiography (analyzed by the core-lab) to exclude left mainstem stenosis. The main exclusion criteria for this trial were: significant
left mainstem stenosis, those with New York Heart Association Class III-to-IV symptoms, percutaneous coronary intervention (PCI) or coronary artery bypass surgery within the last
year, unacceptable angina despite medical therapy, patients
with an ejection fraction (EF) <35%, acute coronary syndrome
(ACS) within two months, and patients with an estimated glomerular filtration rate <30 mL/min or on dialysis. It is also
important to highlight some of the baseline characteristics of
the patients randomized in the trial. The median age was
64 years (interquartile range, 58-70), more than 75% of the
patients were male, and 41.8% of patients overall were diabetic. The median EF was 60% (interquartile range, 55-65). It
is also important to note that when it came to the Seattle angina
questionnaires, just over one-third of patients in both groups
reported no anginal symptoms in the last four weeks, and onefifth of patients reported daily or weekly angina. Overall, the
patients included in this trial could be considered low-risk
patients. It is also prudent to mention that among patients in
the invasive strategy group, 96% underwent angiography and
79% underwent revascularization. In the conservative-strategy
group, 26% of the patients underwent angiography and 21%
underwent revascularization.1,5
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The results of this trial are clinically striking.1,6 To summarize, over a median of 3.2 years, 318 primary outcome events
occurred in the invasive-strategy group and 352 occurred in
the conservative-strategy group. At six months, the cumulative
event rate was 5.3% in the invasive-strategy group and 3.4%
in the conservative-strategy group (difference, 1.9 percentage
points; 95% confidence interval [CI], 0.8-3.0); at five years,
the cumulative event rate was 16.4% and 18.2%, respectively
(difference, 1.8 percentage points; 95% CI, 4.7 to 1.0).
Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to
the definition of myocardial infarction (MI), and a secondary
analysis yielded more procedural MIs of uncertain clinical
importance. There were 145 deaths in the invasive-strategy
group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83-1.32).1
While discussing improvements in anginal symptoms,
again, it is important to remember that 35% of patients is this
study reported no anginal symptoms in the preceding four
weeks. Having said that, patients randomly assigned to the
invasive strategy had greater improvement in angina-related
health status than those assigned to the conservative strategy.
Differences were larger among participants who had more
frequent angina at baseline (8.5 v 0.1 points at three
months and 5.3 v 1.2 points at 36 months among participants with daily or weekly angina compared with no
angina).6 In both arms, the control of cardiovascular risk
factors and compliance with OMT were high, and very few
patients were lost to follow-up.1,6
It is clear that this was a robust, expensive, and large trial
that required patients to undergo a comprehensive noninvasive
evaluation to demonstrate moderate-severe ischemia, with
tight control of cardiovascular risk factors, appropriate OMT
with few patients lost to follow-up. With a trial of this magnitude, however, one must ask what the caveats are and bear
these in mind when interpreting the results before applying
them to clinical practice. First and perhaps most important, is
patient selection. This trial only included low-risk patients
with stable CAD. It excluded those patients with complex anatomic features such as left mainstem disease.
The patients typically were younger, with good left ventricular EFs and with high Seattle anginal questionnaire scores.
This trial also explicitly excluded the most symptomatic
patients (precisely those who were more likely to derive symptomatic benefits from OMT and revascularization) and those
with a recent ACS. Therefore, there appears to be an element
of selection bias.
Slow recruitment rates in certain centers could be interpreted as a tendency for these centers to exclude highly symptomatic patients. When looking at the gender balance of
patients in this trial, it is evident that female patients were
underrepresented. More than three-quarters of the patients in
this trial were male, with female patients comprising 23% of
the total; and when considering the median age of 64 years
and that female patients typically present at an older age, this
trial missed the opportunity to include this important
subgroup.1,6

Although not part of the primary endpoint, it is worth pausing and looking further into the prespecified secondary endpoint of angina reduction. Slightly more than one-third of
patients overall in this study reported no episodes of angina
within the preceding four weeks. Therefore, it may be extrapolated that these patients were unlikely to have a major
improvement in anginal symptoms with either OMT or
revascularization.1,6
This was an important trial that furnished us with important
data on the initial management of stable CAD. One must not
forget to consider the crossover between the groups in this
study. It should be noted that 20% of patients in the invasive
group did not actually receive revascularization, and 21% of
the patients in the conservative group crossed over to receive
revascularization. The strategies of revascularization included
both PCI and surgical revascularization, with slightly more
than one-fourth of the revascularization patients undergoing
surgical revascularization. The ISCHEMIA study also did not
assess lesions with angiographic stenosis of >50% with invasive coronary physiology to confirm functional significance of
said stenosis, and this could be considered a limitation. This is
particularly relevant when interpreting the result of the
ISCHEMIA trial in the context of the FAME-2 trial results in
which fractional flow reserve (FFR) was performed on all
lesions. If the lesion was significant, the patients were randomized to PCI plus OMT versus OMT, and FAME-2 reported
lower even rates in the PCI arm.1,6,7
The authors concluded that this trial did not reveal evidence
that an initial invasive strategy in comparison with an initial
conservative strategy reduced the risk of ischemic cardiovascular events or death from any cause over a median of
3.2 years. Overall, the event rates in this trial were low. It is
unsurprising that the initial conservative strategy had a lower
risk of periprocedural MI. Over time, the divergence of the
curves of spontaneous MI and of the primary endpoint supported revascularization, and this was in the context of the
crossover of 21% of patients in the conservative group receiving revascularization. The conservative group also had lower
rates of heart failure admission with greater symptomatic control, and improved quality of life was noted in the initial invasive strategy, particularly in those with a high burden of
angina.1,6
So How Does This Fit into Daily Clinical Practice?
First and foremost, one needs to remember to keep individual bias in check when it comes to interpreting these results,
before applying them to day-to-day practice. Clinicians also
must be vigilant in not taking a ‘one size fits all’ approach, and
individualization is of the upmost importance. Full disclosure
and presenting both treatment options to patients is paramount,
and involving them in the decision-making process is key. The
lack of mortality benefit demonstrated in this trial may be
influential in the decision-making process for both patients
and the physicians. Indeed, this study reenforced the importance of upfront aggressive OMT in patients presenting with
stable CAD in the context of stable angina symptoms without
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necessarily proceeding directly to a revascularization strategy.
These treatment options should not be seen as competing but
rather as complementary to each other. This is particularly
applicable to younger patients (predominantly male) with preserved EFs. One must be mindful of the patients excluded
from this study, particularly those with left main disease,
reduced EF, New York Heart Association Class III to IV, and
those with unacceptable angina and recent ACS, and not apply
an upfront conservative approach in these patients. In addition,
this study likely will cause a shift away from diagnostic coronary angiography in these patient groups and increase the use
of computed tomography coronary angiography to confirm the
presence of CAD, with invasive strategies reserved for those
who do not respond to OMT or have a high symptom burden.
This may change the profile of the patients ultimately ending
up in catheterization laboratories and have the effect of reducing the number of those lower-risk patients without obstructive
epicardial stenosis ultimately having an invasive angiography.
Overall, this practice-changing study has enhanced significantly the understanding of the management of stable CAD,
challenges clinicians to involve patients in the decision-making process, and likely will influence future clinical practice
guidelines.
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